Abstract

In the absence of new therapeutic strategies, chemotherapeutic drugs are the most widely used strategy against metastatic breast cancer, in spite of eliciting multiple adverse effects and having low responses with an average 5-year patient survival rate. Among the new therapeutic targets that are currently in clinical trials, here, we addressed the association between the regulation of the metabolic process of autophagy and the exposure of damage-associated molecular patterns associated (DAMPs) to immunogenic cell death (ICD), which has not been previously studied. After validating an mCHR-GFP tandem LC3 sensor capacity to report dynamic changes of the autophagic metabolic flux in response to external stimuli and demonstrating that both basal autophagy levels and response to diverse autophagy regulators fluctuate among different cell lines, we explored the interaction between autophagy modulators and chemotherapeutic agents in regards of cytotoxicity and ICD using three different breast cancer cell lines. Since these interactions are very complex and variable throughout different cell lines, we designed a perturbation-based model in which we propose specific modes of action of chemotherapeutic agents on the autophagic flux and the corresponding strategies of modulation to enhance the response to chemotherapy. Our results point towards a promising therapeutic potential of the metabolic regulation of autophagy to overcome chemotherapy resistance by eliciting ICD.

Highlights

  • Breast tumors are the leading cause of cancer-related death per year in the female population [1,2]

  • In order to monitor the autophagic flux in living breast cancer cells, we aimed to produce cell lines with stable expression of the mCHR-GFP-LC3 tandem sensor

  • The central metabolic regulator of autophagy is mammalian target of rapamycin (mTOR), which acts through two different complexes, mTOR complex 1 and mTOR complex 2

Read more

Summary

Introduction

Breast tumors are the leading cause of cancer-related death per year in the female population [1,2]. In the absence of new therapeutic strategies, cytostatic drugs continue to be the most widely used treatment against metastatic breast cancer. This scenario highlights the imperative need to explore new therapeutic approaches for all types of breast cancer, which is definitely a hot research spot nowadays. Among the new therapeutic targets that are currently studied, we address here the regulation of autophagy and the induction of immunogenic cell death (ICD), which, in spite of being related, have not been thoroughly considered to design combined therapeutic approaches

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.